Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q4 2015 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$2.02M$2.02Mderived+2.7% vs Q4 2014 Net Income-$414.65K-$414.65KderivedN/M vs Q4 2014 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$1,081,238+8.6% Operating Incomederived-$415,950N/M Operating Cash Flowderived$27,072−90.1% Free Cash Flowderived$25,525−90.5% Margins · derivedGross margin53.5%+2.9 pt vs Q4 2014
Operating margin-20.6%−32.3 pt vs Q4 2014
Net margin-20.5%−32.3 pt vs Q4 2014
ended Dec 31, 2015 · filed Mar 15, 2016 · 75 d after period end